| Literature DB >> 27657039 |
Francisco J Olivas-Aguirre1, Joaquín Rodrigo-García2, Nina Del R Martínez-Ruiz3, Arely I Cárdenas-Robles4, Sandra O Mendoza-Díaz5, Emilio Álvarez-Parrilla6, Gustavo A González-Aguilar7, Laura A de la Rosa8, Arnulfo Ramos-Jiménez9, Abraham Wall-Medrano10.
Abstract
Anthocyanins (ACNs) are plant secondary metabolites from the flavonoid family. Red to blue fruits are major dietary sources of ACNs (up to 1 g/100 g FW), being cyanidin-3-O-glucoside (Cy3G) one of the most widely distributed. Cy3G confers a red hue to fruits, but its content in raspberries and strawberries is low. It has a good radical scavenging capacity (RSC) against superoxide but not hydroxyl radicals, and its oxidative potential is pH-dependent (58 mV/pH unit). After intake, Cy3G can be metabolized (phases I, II) by oral epithelial cells, absorbed by the gastric epithelium (1%-10%) and it is gut-transformed (phase II &amp; microbial metabolism), reaching the bloodstream (<1%) and urine (about 0.02%) in low amounts. In humans and Caco-2 cells, Cy3G's major metabolites are protocatechuic acid and phloroglucinaldehyde which are also subjected to entero-hepatic recycling, although caffeic acid and peonidin-3-glucoside seem to be strictly produced in the large bowel and renal tissues. Solid evidence supports Cy3G's bioactivity as DNA-RSC, gastro protective, anti-inflammatory, anti-thrombotic chemo-preventive and as an epigenetic factor, exerting protection against Helicobacter pylori infection, age-related diseases, type 2 diabetes, cardiovascular disease, metabolic syndrome and oral cancer. Most relevant mechanisms include RSC, epigenetic action, competitive protein-binding and enzyme inhibition. These and other novel aspects on Cy3G's physical-chemistry, foodomics, and health effects are discussed.Entities:
Keywords: anthocyanin; antioxidant; berries; bioaccessibility; cyanidin; cyanidin 3-O-glucoside; foodomics; phenolic compounds; splanchnic metabolism
Year: 2016 PMID: 27657039 PMCID: PMC6273591 DOI: 10.3390/molecules21091264
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of common anthocyanidins (left) and Cyanidin-3-O-glucoside (Cy3G; right).
Mass spectral data and physicochemical characteristics of Cyanidin (Cy) and glycoside-derivates 1.
| Code | Name | [M]+ ( | MS/MS ( | Solubility (mg/mL) | LogP | Å2 |
|---|---|---|---|---|---|---|
| Cy | Cyanidin (anthocyanidin) | 287 | 0.049 | 3.05 | 114.3 | |
| Cy3A | Cy-3-arabinoside (pentose) | 419 | 287 | 0.41 | 1.06 | 173.21 |
| Cy3X | Cy-3-xyloside | 419 | 287 | 0.41 | 1.06 | 173.2 |
| Cy3G | Cy-3-glucoside | 449 | 287 | 0.6 | 0.39 | 193.4 |
| Cy3Ga | Cy-3-galactoside | 449 | 287 | -- | 0.24 | 193.4 |
| Cy3Aga | Cy-3-(6′′-acetyl)-galactoside | 491 | 287 | 0.39 | 0.82 | 199.5 |
| Cy3Sa | Cy-3-sambubioside | 518 | 287 | -- | -- | -- |
| Cy3,3′′MG | Cy-3-(3′′-malonyl)-glucoside | 535 | 287 | 0.47 | 0.68 | 236.8 |
| Cy3,6′′MG | Cy-3-(6′′-malonyl)-glucoside | 535 | 449/287 | 0.45 | 0.68 | 236.8 |
| Cy3Sa | Cy-3-sambubioside | 581 | 287 | 1.17 | -1.1 | 252.4 |
| Cy3dOXG | Cy-3-(dioxaloyl)-glucoside | 593 | 287 | 0.17 | 2.55 | 280.2 |
| Cy3R | Cy-3-rutinoside | 595 | 449/287 | 0.9 | −1.64 | 252.4 |
| Cy3XR | Cy-3-xylosylrutinoside | 727 | 581/287 | 2.52 | −2.1 | 311.3 |
| Cy3GR | Cy-3-glucosylrutinoside | 757 | 287/611 | 3.85 | −2.8 | 331.5 |
| Cy3,5GG | Cy-3,5-diglucoside | 611 | 449/287 | -- | −2.3 | 272.6 |
| Cy3So | Cy-3-sophoroside | 611 | 287 | -- | -- | 260 |
| Cy3Sa5R | Cy-3-sambubioside-5-rhamnoside | 727 | 581/433/287 | -- | -- | -- |
| Cy3So5R | Cy-3-sophoroside-5-rhamnoside | 757 | 611/433/287 | -- | -- | -- |
1 See abbreviations section for non-defined terms.
Voltammetric oxidation of and Cy3G and its aglycone 1.
| Molecule | pH | Epa/mV | Technique | Electrodes | Ref. |
|---|---|---|---|---|---|
| Cy3G | 3.5 | 490, 980 | DPV | WE: Glassy carbon | [ |
| 4.5 | 420, 815 | ||||
| 7.0 | 310, 500 | ||||
| Cy3G | 2.2 | 548 | CV | WE: Glassy carbon | [ |
| 4.8 | 400 | ||||
| 5.9 | 310 | ||||
| 6.9 | 230 | ||||
| Cy3G | 2.0 | 500 | ASSWV | WE: Paraffin rod impregnated | [ |
| Cy | 403 | ||||
| Cy3G | 1.0 | 617 | CV | WE: Platinum | [ |
1 See abbreviations section for the meaning of each term.
Figure 2Anthocyanin biosynthesis. Cy3G main steps and crossroads. See abbreviations section for the meaning of each term.
Cyanidin-3-O-glucoside (Cy3G) content in selected edible sources 1.
| Group | Fruit/Vegetable | Cy3G 2 | Major ACNs 3 |
|---|---|---|---|
| Fruits/Berries | Black elderberry | 794.13 | Cy3G |
| Blackberry raw | 138.72 | Cy3G | |
| Black Aestivalis grape | 18.72 | Cy3G | |
| Gooseberry | 2.95 | Cy3G | |
| Nectarine peeled | 0.56 | Cy3G | |
| Peach peeled | 0.28 | Cy3G | |
| Blackcurrant raw | 25.07 | Dp3R (304.91) | |
| Black chokeberry | 19.64 | Cy3A (252.76) | |
| Blueberry | 14.2 | Dp3G (22.6) | |
| Sweet cherry raw | 18.73 | Cy3R (143.27) | |
| Red raspberry | 14.89 | Cy3So (37.61) | |
| Raspberry pomace (dry) | 41.52 | Cy3So (100.1) | |
| Plum fresh | 8.63 | Cy3R (33.85) | |
| Lowbush blueberry | 7.5 | Mv3G (26.06) | |
| Redcurrant | 3.37 | Cy3XR (11.22) | |
| Strawberry | 2.88 | Pg3G (47.1) | |
| Lingonberry | 1.42 | Cy3Ga (48.69) | |
| Highbush blueberry | 1.37 | Dp3Ga (20.50) | |
| Sour cherry | 1.12 | Cy3GR (43.63) | |
| Black grape | 1.08 | Mv3G (39.23) | |
| American Cranberry | 0.74 | Pn3Ga (22.02) | |
| Cloudberry | 0.62 | Cy3R (1.86) | |
| Juices/wine | Pomegranate pure juice | 3.43 | Cy3G |
| Blood orange pure juice | 1.41 | Cy3MG (1.76) | |
| Red wine | 0.21 | Mv3G (9.97) | |
| Cereals/legumes | Black bean raw | 3.99 | Dp3G (20.50) |
| Blue maize hybrid | 2.25 | Cy3G | |
| Vegetables | Black Olive raw | 10.62 | Cy3R (72.35) |
| Red lettuce raw | 0.62 | Cy3MG (2.91) |
1 See Table 1 and abbreviations section for the meaning of term 2 Average content (mg per 100 mL or 100 g FW), 3 (average content).
Figure 3Cy3G metabolic fate in humans. Expressed as percentage of original Cy3G intake. See abbreviations section for the meaning of term.
Figure 4Time-course bioavailability of Cy3G and its main metabolites. Note: The absorption and biotransformation of cyanidin-3-O-glucoside (Cy3G) into derivates and metabolites are depicted clockwise in this figure and explained in detail within the text. See abbreviations section for the meaning of terms.
Cy3G associated effects-cell lines.
| Cell Line | Cy3G dose | Mechanism | Ref. |
|---|---|---|---|
| Erythrocytes | 10–100 μM | ↓ cholesterol and TBAR in cell membranes | [ |
| Human adherent macrophages (from U937 cells), oral epithelial cells (GMSM-K) and gingival fibroblasts (HGF-1) | 5–25 μg/mL | ↓ IL-6 level (macrophages), cytoprotection (GMSM-K, HGF-1) against nicotine toxicity | [ |
| Colon (Caco2), liver (HepG2), prostate (PC3) | Blue maize ACNs (189–500 μg/g)-extract | ↓ cell proliferation | [ |
| Gastric cancer (KATO III) | 12.5 μM | ↓ Helicobacter pylori VacA-induced cell death | [ |
| Adipocytes (3T3-L1) | 50 μM | ↓ FoxO1-mediated transcription of lipase | [ |
| Hepatome (HepG2) | 1–100 μM | ↑ fatty acid oxidation and AMPK activity | [ |
| Adipocyte | 0.5–50 μM + docosahexanoic acid | ↓ basal lipolysis , inflammatory markers | [ |
| Breast cancer (BT474m MD-MB231, MCF7) | 10 μM | ↓ invasion / increased expression of ErB2 | [ |
| Murine thymoma (EL-4T) | 2.5–5.0 μg/mL | ↓ Il-3 & IL-4 by GATA-3 inhibition | [ |
| Pheochromocytoma (PC-12) | IC50, 15.3 μg/mL | ↓ ATP-induced [Ca2+] increase | [ |
| Colon cancer (HT-29) | 25 μM | ↓ IL-8, nitrite, PGE2 | [ |
| human aortic epithelial cells | 0.5–50 μM | ↑ oxiesterol efflux, ↑ABCG1/ABCA1 expression | [ |
| Heart (isolated mitochondria) | 20 Μm | ↑ phosphorylation, ATP production, ↑e− carrier | [ |
| Adipocytes (steam cells) | 100 μg/mL | ↓ IL-6 level | [ |
| Ovarian cancer (HO-8910PM) | IC50, 13.8 μg/mL | ↑ apoptosis, ↓mucin 4 expression | [ |
Cy3G associated effects-rodent models.
| Model | Protocol (Dose) | Effects | Ref. |
|---|---|---|---|
| Mice (nude), SKH-1 | Oral | ↓ lipid per oxidation ↑ Glutathione | [ |
| Mice, C57BL/6 | Oral, 24 h before, (2 mg/kg) | ↓ Neuronal apoptosis reducing factor, superoxide level, infarct size | [ |
| Mice (obese), C57BL/6 | Oral, 5 w, 0.02% diet, ( | Antidiabetic by modulating c-jun N-terminal kinase | [ |
| Mice, apoE (-) | Oral, 12 w, 0.06% diet, ( | ↓ expression of hepatic cholesterol 7a-hydroxylase | [ |
| Mice, ovarian cancer | Oral, 2 w, (5 mg/kg) | ↓ Growth of ovarian xenograft tumors | [ |
| Mice, C57BL/6 | Oral, 12 w, (40–200 mg/kg) | ↓ weigh gain, insulin resistance, adiposity, leptin | [ |
| Mice, apoE (-) | Oral, 8 w, 0.2% diet ( | ↓ atherogenesis, ↑endothelial repair | [ |
| Mice, with peritonitis/edema | Oral, 30–60 min before (40 mg/kg) | ↓ inflammation, expression COX-2/PGE2 | [ |
| Mice, diabetic | Oral, 4 w, (300 µg/10g) | ↓ blood glucose | [ |
| Mice, KK-Ay | Oral | ↓ visceral fat ↑ lipoprotein lipase | [ |
| Mice, C57BL/6 w/acute alcohol-induced liver injury | Oral, 24–48 h, (10 mg/kg) | ↓ plasma IL-6 ,TNF-α, ALT and AST and ↑ SIRT1 p-c-Jun and Bax expression | [ |
| Rats (retinal degeneration) | Oral, 5 w, 100 mg/kg | ↓ Loss of photoreceptors | [ |
| Mice (fetus) | Intra-peritoneal 10–30 mg/kg | ↓Neuronal damage by caspase 3 inhibition | [ |
| Rats (β-amyloidosis) | Oral, 30 day, 10 mg/kg | ↓ cognitive impairment induced by Aβ via the modulation of GSK-3β/tau | [ |
Figure 5Docking simulation of Cy3G and Cy toward porcine lipase/colipase complex. Docking simulation details are described in Section 5.3. Cy3G (left) and Cy (right) within (A,B, light green) and near (C,D; light blue) the active site of lipase (dark grey) and at the binding region with colipase (intense blue; E,F).
Figure 6Docking simulation of Cy3G and Cy toward porcine amylase. Docking simulation details are described in Section 5.3. Cy3G (A); Cy (B) within enzyme’s (light grey) active site (green).